Obermatt
See Similar Stocks →

JW Pharmaceutical

KSC:001060 · KR7001060003
PharmaceuticalsSmall

360

95
Medium confidence — indicative
EV / EBIT87
Price / Owner Earnings31
Owner Earnings Yield89
Dividend Yield1
Price/Sales46
EV / Gross Profit85
Price/Book26
Return on Capital93
Cash Return on Capital93
Return on Equity96
EBIT Margin81
Gross Profitability98
Cash Conversion53
Accruals37
Owner Earnings Margin75
Sales growth60
Profit Growth73
Long-Term EPS Growth51
Owner Earnings Growth67
Reinvestment17
Price momentum78
Debt load78
Refinancing22
Debt Payback100
Liquidity80
Analyst ratings93
Expectations trend50
Market mood73
Value Creation18/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

JW Pharmaceutical generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeKOSE
Employees104
Websitejw-pharma.co.kr
ISINKR7001060003
Last UpdateApr 2, 2026
Indices
KOSPI (South Korea)
Themes
OphthalmologyWomen's HealthCardiovascularOncologyBiotechnologyHealth CarePharmaceutical

Description

Analysis

Hidden champion

JW Pharmaceutical Corporation fits the profile of a hidden champion, yet the market has not awarded it the premium its quality earns. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is attractive. The owner-earnings multiple stands at 7.2×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is sturdy. The company scores 18/20 on our value-creation score: strong value creator.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
49
2023202420252026

All-time high

78

Jan 2025

All-time low

11

Jan 2023

Average rank

41

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
46
87
68
92
Price/Earnings
66
90
58
81
Price/Book
26
29
25
30
Dividend Yield
1
44
37
40
Value (overall)
29
68
42
53

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare JW Pharmaceutical with its peers
JW
KSC:096760
97
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
GC Biopharma
KSC:006280
52
CountrySouth Korea
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Hanmi Pharmaceutical
KSC:128940
76
CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Dong-A Socio
KSC:000640
85
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Eisai
TYO:4523
70
CountryJapan
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Hyundai Pharmaceutical
KSC:004310
33
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →